
US FDA grants standard approval of Eisai/Biogen Alzheimer’s drug
By Deena Beasley and Julie Steenhuysen LOS ANGELES (Reuters) -Eisai and Biogen’s Leqembi won a coveted standard approval nod from the U.S. Food and Drug Administration on Thursday, the first Alzheimer’s treatment to achieve that goal, clearing the way for wider insurance coverage of the drug. The FDA decision marks a new milestone for a…